Oncolytics Biotech Inc T.ONC

itntdf

[pelaboost]

I have not been following a closely as I used to do. There are other things to do, garden et cetera.

My take is as follows: The 5 million accelerator award enables  a clinical trial with pela and modified FOLFIRINOX with and without an ICI. This grant was a surprise and renders the 90 day thing no longer a thing. If succesful this trial gets added into the Precision Promise Trial. The potential patient population will be much larger. It is worth the wait. There are a lot of moving parts here.

It will take a bit of time; we cannot afford any mistakes.

Best.

[itntdf]

That would seem to be a case of 1 + 1 equals 0 and That doesn’t seem to square with the facts.   When PanCan selected Oncy, it was to go into a Phase 3 clinical trial as stated in the following PR:   SAN DIEGO, CA and CALGARY, AB, June 22, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced pelareorep has been selected for inclusion as a

[pelaboost]

@itntdf. You have always had a better understanding of these matters. I thought (as a layman; not a good idea) that because of the grant being a surprise there was a delay in the start of Precision Promise to allow for the additional arm that might come out of the newly enabled FOLFIRINOX trial. So a bit of a delay on Precision Promise, it starts, and later the FOLFIRINOX arm may or may not be